Nonparametric expectation maximization population modeling of ganciclovir

Journal of Clinical Pharmacology

Volumn 36, Issue 4, 1996, Pages 301-310

  Preston, Sandra L ^a   Drusano, George L ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MATHEMATICAL ANALYSIS; PARAMETER; PHARMACOKINETICS; POPULATION MODEL; RETINITIS;

EID: 0029930543     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04205.x     Document Type: Article

References (20)

1. Beal S, Sheiner L: NONMEM User's Guide, port I: User's Basic Guide. Technical Report of the Division of Clinical Pharmacology. San Francisco: University of California, 1980.
2. Jonkman JHG, Upton RA: Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984;9:3-9.
3. Schumitzky A: Nonparametric EM algorithms for estimating prior distributions. Appl Math Comput 1991;45:143-157.
4. Mallet A: A maximum likelihood estimation method for random coefficient regression models. Biometrika 1986;73:645-656.
5. Yuen GJ, Drusano GL, Fletcher C, Capparelli E, Connor JD, Lalezari JP, et al: Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling. Antimicrob Agents Chemother 1995;39:2350-2352.
6. Fuseau E, Sheiner LB: Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model. Clin Pharmacol Ther 1984;35:733-741.
7. Sheiner LB, Grasela TH: Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data. Drug Metab Rev 1984;15:293-303.
8. Grasela TH, Sheiner LB: Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet 1984;9: 545-554.
9. Maire P, Barbaut X, Girard P, Mallet A, Jelliffe RW, Berod T: Preliminary results of three methods for population pharmacokinetic analysis (NONMEM, NPML, NPEM) of amikacin in geriatric and general medicine patients. Int J Biomed Comput 1994;36:139-141.
10. Gilman TM, Brunnemann SR, Segal JL: Comparison of population pharmacokinetic models for gentamicin in spinal cord-injured and able-bodied patients. Antimicrob Agents Chemother 1993;37:93-99.
11. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37: 1073-1081.
12. Drusano GL, Aweeka F, Gambertoglio J, Jacobson M, Lane C, Polis M, Eaton C, Martin-Munley S: Relationship between foscarnet exposure and time to progression of CMV retinitis (abstract). In, Program and Abstracts of the Second National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29-February 2, 1995. Washington, DC: American Society for Microbiology, 1995; abstract no. 500.
13. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Kupperman BD, Quiceno JI, Flores-Aguilar M, Connor JD, Capparelli EV, Sherwood CH, Freeman WR: Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993;168:1506-1509.
15. D'Argenio DZ, Schumitzky A: ADAPT II: A Program for Simulation, Identification, and Optimal Experimental Design; Users manual. Los Angeles, CA: Biomedical Simulations Resource, University of Southern California, 1992.
16. Whiting B, Kelman AW, Grevel J: Population pharmacokinet-ics theory and clinical application. Clin Pharmacokinet 1986;11: 387-401.
17. Sheiner LB, Beal S, Rosenberg B, Marathe W: Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979;26:294-305.
18. Jelliffe RW, Schumitzky AM, Van Guilder M, Liu M, Hu L, Maire P, et al: Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993;15:380-393.
19. Forrest A, Hawtoff J, Egorin MJ: Evaluation of a new program for population PK/PD analysis: applied to simulated phase 1 data (abstract). Clin Pharmacol Ther 1991;49:153.
20. Forrest A, Ballow CH, Nix DE, Birmingham MC, Schentag JJ: Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37:1065-1072.